Overview
Cystic fibrosis is a complex and debilitating disease that affects approximately 70,000 people worldwide. It is caused by a mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, which codes for a protein responsible for regulating the movement of salt and water in and out of cells. This mutation leads to the production of thick, sticky mucus that clogs the airways, digestive tract, and other organs, causing a range of symptoms and complications.
CF is an autosomal recessive disorder, meaning that a person must inherit two copies of the mutated gene (one from each parent) to develop the condition. Carriers of the mutation, who have one normal and one mutated gene, are generally asymptomatic but can pass the mutated gene to their offspring. The disease is most commonly diagnosed in children, but it can also be diagnosed in adults who have not previously been diagnosed.
History/Background
Cystic fibrosis was first described in 1938 by Dr. William E. Knowles and Dr. Asa G. Schwartz, who noted the presence of thick, sticky mucus in the airways of affected individuals. However, it was not until the 1950s and 1960s that the genetic basis of the disease was understood. In 1989, the CFTR gene was identified, and in 1993, the first CFTR gene mutation was discovered. Since then, numerous mutations have been identified, and genetic testing has become a crucial tool in diagnosing and managing the condition.
Key Information
Cystic fibrosis is characterized by a range of symptoms, including:
* Respiratory symptoms: persistent cough, wheezing, shortness of breath, and recurrent lung infections
* Gastrointestinal symptoms: abdominal pain, bloating, and malnutrition due to pancreatic insufficiency
* Reproductive symptoms: infertility in males and recurrent miscarriages in females
* Other symptoms: clubbing of the fingers and toes, and increased risk of osteoporosis and diabetes
Key milestones in the management of CF include:
* Pulmonary function tests: regular monitoring of lung function to assess disease progression and response to treatment
* Medications: use of bronchodilators, antibiotics, and pancreatic enzyme supplements to manage symptoms and prevent complications
* Lung transplantation: a life-saving option for individuals with severe lung damage
* Gene therapy: ongoing research into the use of gene editing technologies to correct the CFTR gene mutation
Significance
Cystic fibrosis is a significant public health concern, with a median life expectancy of 47 years for individuals born in 2020. However, with advances in medical care and management, many individuals with CF are living well into adulthood. The disease has also led to significant advances in our understanding of genetics, gene therapy, and respiratory medicine.
